Clinical significance of urinary soluble CD11b and CD163 receptor levels in ANCA-associated vasculitides

Objective. To assess the diagnostic value of urinary soluble CD11b and CD163 receptor levels (U-CD11b and U-CD163) in patients with antineutrophil cytoplasmic antibody-associated systemic vasculitides (AAV).
Material and methods. This cross-sectional study included 48 patients (21 men, 27 women; median age 52 [31; 67] years) with a confirmed diagnosis of AAV: granulomatosis with polyangiitis (GPA) in 38, microscopic polyangiitis (MPA) in 8, and eosinophilic granulomatosis with polyangiitis in 2. Patients were stratified into two groups: Group 1, AAV without kidney involvement (n=25); Group 2, AAV with kidney involvement (n=23). A comparison Group 3 comprised 13 patients with systemic lupus erythematosus (SLE) and biopsy-proven kidney involvement (4 men, 9 women; median age 34 [29.0; 43.4] years). All patients underwent standard clinical, laboratory, and instrumental evaluations. U-CD11b and U-CD163 were measured by ELISA using kits ELH-ITGAM-1 (human CD11b) and DC1630 (human CD163) (China). Reference values for U-CD11b and U-CD163, established as the 95th percentile in volunteers without autoimmune disease, were 5.7 and 41.4 ng/mL, respectively. In 10 patients (2 with GPA, 1 with MPA, and 7 with SLE) glomerulonephritis (GN) was verified by vital renal biopsy.
Results and discussion. GN was identified in 36 patients (23 with AAV, 13 with SLE). U-CD11b level was significantly higher in 8 (61.5%) SLE patients than in 22 (46%) AAV patients (median 8.2 [4.5; 11.1] and 5.1 [2.7; 8.1] ng/mol, respectively; p=0.02). Conversely, U-CD163 level was higher in 13 (48%) AAV patients (median 29.8 [3.5; 159.1] ng/mmol) than in 6 (46.1%) SLE patients (22.6 [12.7; 148.5] ng/mol), p=0.04. Elevated U-CD11b was detected more frequently in SLE and in AAV with kidney involvement than in AAV without kidney involvement (61.5%, 56.5%, and 36%, respectively; p=0.001), with the highest median in Group 3 (median 8.2 [4.5; 11.1] ng/mmol). Elevated U-CD163 was more frequent in Groups 3 and 2 than in Group 1 (46.1%, p=0.009; 43.4%, p=0.025; and 12%, respectively), with the highest median in Group 2 (34.9 [9.3; 159.1] ng/mmol). However, between-group differences in the frequencies of elevated U-CD11b and U-CD163 were not statistically significant. In Group 1, increases in U-CD11b (36% of cases) and U-CD163 (12%) levels were also observed. Elevated biomarker levels were associated with higher disease activity but not with GN morphological classes in AAV or SLE.
Conclusion. U-CD11b and U-CD163 levels may reflect the severity of renal inflammatory involvement in patients with AAV and SLE. Further studies are needed to determine the diagnostic utility of these biomarkers.

1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. doi: 10.1002/art.37715.

2. Fijolek J, Wiatr E. Antineutrophil cytoplasmic antibodies – their role in pathogenesis, diagnosis and treatment monitoring of ANCA-associated vasculitis. Cent Eur J Immunol. 2020;45(2):218-227. doi: 10.5114/ceji.2019.92494

3. Bossuyt X, Cohen Tervaert JM, Arimura Y, Blockmans D, Flores-Suarez LF, Guillevin L, et al. Position paper: revised 2017 international consensus on testing of ANCA in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol. 2017 Nov; 13(11):683-692. doi:10.1038/nrrheum.2017.140.

4. Egorova ON, Tarasova GM, Isaeva BG, et al. On the problem of differential diagnosis in the detection of antineutrophil cytoplasmic antibodies. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2024;18(2):7-15. (In Russ.). doi: 10.14412/1996-7012-2024-2-7-15.

5. Hilhorst M, Wilde B, van Breda Vriesman P, et al. Estimating renal survival using the ANCA-associated GN classification. J Am Soc Nephrol. 2013 Sep;24(9):1371-5. doi: 10.1681/ASN.2012090912.

6. Moiseev S, Novikov P, Jayne D, Mukhin N. End-stage renal disease in ANCA-associated vasculitis. Nephrol Dial Transplant. 2017 Feb 1;32(2):248-253. doi: 10.1093/ndt/gfw046.

7. Floege J, Jayne DRW, Sanders JSF, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis. Kidney Int. 2024 Mar; 105(3):447-449.doi: 10.1016/j.kint.2023.10.009.

8. Wu I, Parikh CR. Screening for kidney diseases: older measures versus novel biomarkers. Clin J Am Soc Nephrol. 2008 Nov;3(6):1895- 901. doi: 10.2215/CJN.02030408.

9. Oomatia A, Moran SM, Kennedy C, et al. Prolonged duration of renal re covery following ANCA-associated glomerulonephritis. Am J Nephrol. 2016;43(2):112-9. doi: 10.1159/000444925.

10. Kronbichler A, Shin JI, Lee KH, et al. Clinical associations of renal involvement in ANCA-associated vasculitis. Autoimmun Rev. 2020 Apr;19(4):102495. doi: 10.1016/j.autrev.2020.102495.

11. Odler B, Bruchfeld A, Scott J, et al. Challenges of defining renal response in ANCA-associated vasculitis: call to action? Clin Kidney J. 2023 Jan 11;16(6):965-975. doi: 10.1093/ckj/sfad009.

12. Kitching AR, Anders HJ, Basu N, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020 Aug 27;6(1):71. doi: 10.1038/s41572-020-0204-y.

13. Kronbichler A, Bajema IM, Bruchfeld A, et al. Diagnosis and management of ANCA-associated vasculitis. Lancet. 2024 Feb 17;403(10427):683-698. doi: 10.1016/S0140-6736(23)01736-1.

14. Kemna MJ, Damoiseaux J, Austen J, et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol. 2015 Mar;26(3):537-42. doi: 10.1681/ASN.2013111233.

15. Casal Moura M, Specks U, Tehranian S, et al. Maintenance of remission and risk of relapse in myeloperoxidase-positive ANCA-associated vasculitis with kidney involvement. Clin J Am Soc Nephrol. 2023 Jan 1;18(1):47-59. doi: 10.2215/CJN.06460622.

16. Novikov P, Smitienko I, Bulanov N, et al. Testing for antineutrophil cytoplasmic antibodies (ANCAs) in patients with systemic vasculitides and other diseases. Ann Rheum Dis. 2017 Aug;76(8):e23. doi: 10.1136/annrheumdis-2016-210890.

17. Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024 Jan 2; 83(1):30-47. doi: 10.1136/ard-2022-223764.

18. Slot MC, Tervaert JW, Franssen CF, Stegeman CA. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int .2003 Feb;63(2):670-7. doi: 10.1046/j.1523-1755.2003.00769.x.

19. Rhee RL, Davis JC, Ding L. The utility of urinalysis in determining the risk of renal relapse in ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2018 Feb 7;13(2):251-257. doi: 10.2215/CJN.04160417.

20. Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001 Jan 11;409(6817): 198-201. doi: 10.1038/35051594.

21. Etzerodt A, Moestrup SK. CD163 and inflammation: Biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal. 2013 Jun 10;18(17):2352-63. doi: 10.1089/ars.2012.4834.

22. O’Reilly VP, Wong L, Kennedy C, et al. Urinary soluble CD163 in active renal vasculitis. J Am Soc Nephrol. 2016 Sep;27(9):2906-16. doi: 10.1681/ASN.2015050511.

23. Moran SM, Monach PA, Zgaga L, et al. Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant. 2020 Feb 1;35(2): 283-291. doi: 10.1093/ndt/gfy300.

24. Rousselle A, Kettritz R, Schreiber A. Monocytes promote crescent formation in anti-myeloperoxidase antibody-induced glomerulonephritis. Am J Pathol. 2017 Sep; 187(9):1908-1915. doi: 10.1016/j.ajpath.2017.05.003.

25. Zhao L, David MZ, Hyjek E, et al. M2 macrophage infiltrates in the early stages of ANCA-associated pauci-immune necrotizing GN. Clin J Am Soc Nephrol. 2015 Jan 7;10(1): 54-62. doi: 10.2215/CJN.03230314.

26. Kitagawa A, Tsuboi N, Yokoe Y, et al. Urinary levels of the leukocyte surface molecule CD11b associate with glomerular inflammation in lupus nephritis. Kidney Int. 2019 Mar; 95(3):680-692. doi: 10.1016/j.kint.2018.10.025.

27. Hou L, Koutsogiannaki S, Yuki K. Multifaceted, unique role of CD11c in leukocyte biology. Front Immunol. 2025 Mar 4;16: 1556992. doi: 10.3389/fimmu.2025.1556992.

28. Zen K, Guo YL, Li LM, et al. Cleavage of the CD11b extracellular domain by the leukocyte serprocidins is critical for neutrophil detachment during chemotaxis. Blood. 2011 May 5;117(18):4885-94. doi: 10.1182/blood-2010-05-287722.

29. Yokoe Y, Tsuboi N, Imaizumi T, et al. Clinical impact of urinary CD11b and CD163 on the renal outcomes of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Nephrol Dial Transplant. 2021 Jul 23;36(8):1452-1463. doi: 10.1093/ndt/gfaa097.

30. Robson JC, Grayson PC, Ponte C, et al; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Arthritis Rheumatol. 2022 Mar;74(3):393-399. doi: 10.1002/art.41986.

31. Suppiah R, Robson JC, Grayson PC, et al; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Arthritis Rheumatol. 2022 Mar;74(3):400-406. doi: 10.1002/art.41983.

32. Grayson PC, Ponte C, Suppiah R et al; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Arthritis Rheumatol. 2022 Mar; 74(3):386-392. doi: 10.1002/art.41982.

33. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug; 64(8): 2677-86. doi: 10.1002/art.34473.

34. Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010 Oct;21(10):1628-36. doi: 10.1681/ASN.2010050477.

35. Kronbichler A, Kerschbaum J, Gründlinger G, et al. Evaluation and validation of biomarkers in granu lomatosis with polyangiitis and microscopic polyangiitis. Nephrol Dial Transplant. 2016 Jun;31(6): 930-6. doi: 10.1093/ndt/gfv336.

36. Bulanov NM, Serova AG, Kuznetsova EI, et al. Renal tissue damage molecules (KIM-1, MCP-1) and type IV collagen in assessing the activity of glomerulonephritis associated with antineutrophil cytoplasmic antibodies. Terapevticheskii arkhiv. 2017;89(6):48-55. (In Russ.).

37. Al-Hussain T, Hussein MH, Conca W, et al. Pathophysiology of ANCA-associated Vasculitis. Adv Anat Pathol. 2017 Jul;24(4): 226-234. doi: 10.1097/PAP.0000000000000154.

38. Vorkel' EN, Reshetnyak TM, Nurbaeva KS, et al. Serum calprotectin in vasculitis associated with antineutrophil cytoplasmic antibodies. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2024;18(4):66-73. (In Russ.). doi:10.14412/1996-7012-2024-4-66-73.

39. Fava А, Buyon J, Magder L, et al. Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI Insight. 2024 Jan 23;9(2): e172569. doi: 10.1172/jci.insight.172569.

40. Nielsen MC, Andersen МN, Rittiget N, et al. The macrophage-related biomarkers sCD163 and sCD206 are released by different shedding mechanisms. J Leukoc Biol. 2019 Nov; 106(5):1129-1138. doi: 10.1002/JLB.3A1218-500R.

41. Olmes G, Büttner-Herold M, Ferrazzi F, et al. CD163+ M2c-like macrophages predominate in renal biopsies from patients with lupus nephritis. Arthritis Res Ther. 2016 Apr 18: 18:90. doi: 10.1186/s13075-016-0989-y.

42. Li J, Jo MH, Yan J, et al. Ligand binding initiates single-molecule integrin conformational activation. Cell. 2024 Jun 6; 187(12): 2990-3005.e17. doi: 10.1016/j.cell.2024.04.049.

43. Endo N, Tsuboi N, Furuhashi K, et al. Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritis. Nephrol Dial Transplant. 2016 Dec; 31(12): 2023-2033. doi: 10.1093/ndt/gfw214.

44. Droste A, Sorg C, Hogger P. Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteinerich family. Biochem Biophys Res Commun. 1999 Mar 5;256(1):110-3. doi: 10.1006/bbrc.1999.0294.

45. Moller HJ, Peterslund NA, Graversen JH, et al. Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood. 2002 Jan 1;99(1): 378-80. doi: 10.1182/blood.v99.1.378.